|
Mechanismα1A-AR antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date07 Aug 1987 |
[Translation] Human Bioequivalence Study of Terazosin Hydrochloride Tablets
本试验为正式试验,旨在研究单次空腹口服海南绿岛制药有限公司研制、生产的盐酸特拉唑嗪片(2 mg)的药代动力学特征;以Aesica Queenborough Limited生产的盐酸特拉唑嗪片(Hytrin®,2 mg)为参比制剂,比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞、Tmax,评价两制剂的生物等效性。
[Translation] This test is a formal test to study the pharmacokinetic characteristics of terazosin hydrochloride tablets (2 mg) developed and produced by Hainan Ludao Pharmaceutical Co., Ltd. after a single fasting oral administration; Zine tablet (Hytrin®, 2 mg) was used as the reference preparation. The pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞ and Tmax of the two preparations were compared, and the bioequivalence of the two preparations was evaluated.
100 Clinical Results associated with Hainan Green Island Pharmacentical
0 Patents (Medical) associated with Hainan Green Island Pharmacentical
100 Deals associated with Hainan Green Island Pharmacentical
100 Translational Medicine associated with Hainan Green Island Pharmacentical